Purpose: The aim of this study was to develop a mobile app-based musculoskeletal exercise program (AMSEP) for operating room (OR) nurses and evaluate its effects on self-efficacy, the flexibility of the shoulders, lower back, and legs, and musculoskeletal symptoms and fatigue. Methods: The AMSEP was developed based on the information-motivation-behavioral skill model. In total, 48 OR nurses were recruited at a university hospital in Korea and divided into an experimental group (n=24) and a control group (n=24), matched for career experience in the OR. The experimental group participated in the AMSEP, while the control group received a booklet regarding musculoskeletal exercise. Results: The experimental group showed significant increases in self-efficacy (t = -2.77, p = .008) and flexibility of the right shoulder (t = -4.08, p < .001), left shoulder (t = -3.28, p = .002), lower back (t = -3.75, p < .001), and legs (t = -3.96, p < .001) compared to the control group. Musculoskeletal symptoms (t = 2.75, p = .008), and fatigue (Z = -1.98, p = .048) significantly decreased in the experimental group compared to the control group. Conclusion Our findings indicate that the AMSEP for OR nurses provided information on the prevention of musculoskeletal disorders and methods of exercise, as well as an opportunity for continued exercise performance through self-management. The AMSEP was easily accessible and effective in increasing self-efficacy and flexibility and reducing musculoskeletal symptoms and fatigue.

Background/Aims: Fluoroquinolone-containing triple eradication therapy could be considered an alternative regimen for the second- line treatment of Helicobacter pylori infection. This study aimed to investigate the changes in the eradication efficacy of fluoroquinolone- containing triple therapy from 2003 to 2018 in Korea. Materials and Methods: Patients with a history of first-line eradication therapy failure were consecutively enrolled at Seoul National University Bundang Hospital from 2003 to 2018. All patients took moxifloxacin-containing triple therapy as the second-line eradication therapy. The treatment regimen comprised a three-drug combination comprising a proton pump inhibitor, amoxicillin, and moxifloxacin. Data on age, sex, endoscopic diagnosis, eradication results, compliance, and adverse outcomes were acquired and analyzed. Results: In total, 824 participants were enrolled during the study period, of whom, 46 were lost to follow-up. Finally, 778 participants were included in the per-protocol (PP) analysis, of whom, 72.1% received moxifloxacin-containing triple therapy for 14 days. The eradication rate of moxifloxacin-containing triple therapy was 72.1% (594/824) in the intention-to-treat analysis and 76.3% (594/778) in the PP analysis. A decline in eradication efficacy was observed, especially in the PP analysis (P=0.046). Diarrhea was the most commonly observed adverse event, accounting for 19.6% (41/209) of recorded adverse events. Conclusions Moxifloxacin-containing triple therapy has shown suboptimal eradication efficacy as the second-line eradication therapy. In addition, there is a concern that eradication rate will decrease due to increase in antimicrobial resistance.